BioNxt Solutions

BioNxt Solutions (BNXTF) completed a debt settlement with an arm’s length creditor, settling a $225,010 debt via share issuance (112,505 shares at CAD$1.00) and a $112,505 cash payment. The newly issued shares are subject to a four-month and one-day holding period according to CSE policies. This move aims to strengthen financial footing while preserving cash for core operations, though it may result in minor shareholder dilution. BioNxt focuses on bioscience innovation, particularly drug delivery technologies.